Abstract: An object of the present invention is to provide a powder of high-purity 1,4-cyclohexanedicarboxylic acid with excellent powder flowability. The invention provides a powder of high-purity 1,4-cyclohexanedicarboxylic acid having particle size distributions (volume basis) such that D10 is within a range of 5 to 55 ?m, D50 is within a range of 40 to 200 ?m, and D90 is within a range of 170 to 800 ?m; and having an aerated bulk density of 0.4 to 0.8 g/cm3, a packed bulk density of 0.5 to 1.0 g/cm3, and a compressibility of 10 to 23%.

Abstract: An object of the present invention is to provide a powder of high-purity 1,4-cyclohexanedicarboxylic acid with excellent powder flowability. The invention provides a powder of high-purity 1,4-cyclohexanedicarboxylic acid having particle size distributions (volume basis) such that D10 is within a range of 5 to 55 ?m, D50 is within a range of 40 to 200 ?m, and D90 is within a range of 170 to 800 ?m; and having an aerated bulk density of 0.4 to 0.8 g/cm3, a packed bulk density of 0.5 to 1.0 g/cm3, and a compressibility of 10 to 23%.

Abstract: A sludge receiving facility is provided with upper and lower structures respectively having inner spaces communicating with each other, wherein sludge tanks each having a sludge charging port are provided in the lower structure, and a partition wall configured to partition a carrying-in space of the upper structure from the inner space is provided, the sludge receiving facility including: outside air blowing means; air circulating means configured to enable the inner space and the carrying-in space to communicate with each other; first exhausting means configured to exhaust air from an upper part of the carrying-in space; second exhausting means configured to exhaust air above the sludge charging port; and third exhausting means configured to exhaust air inside the sludge tanks, wherein opening/closing means are respectively provided in the circulating means and the first to third exhausting means.

Abstract: Disclosed are, for example, a process for producing a tricarboxylic acid tris(alkyl-substituted cyclohexylamide), the process comprising subjecting a tricarboxylic acid and an alkyl-substituted cyclohexylamine to an amidation reaction, either (a) in the presence of a boric acid compound and a phenol compound or (b) in the presence of a boric acid ester obtained by the dehydration condensation of a boric acid compound and a phenol compound, and optionally purifying the resulting crude reaction product.

Abstract: A sludge receiving facility is provided with upper and lower structures respectively having inner spaces communicating with each other, wherein sludge tanks each having a sludge charging port are provided in the lower structure, and a partition wall configured to partition a carrying-in space of the upper structure from the inner space is provided, the sludge receiving facility including: outside air blowing means; air circulating means configured to enable the inner space and the carrying-in space to communicate with each other; first exhausting means configured to exhaust air from an upper part of the carrying-in space; second exhausting means configured to exhaust air above the sludge charging port; and third exhausting means configured to exhaust air inside the sludge tanks, wherein opening/closing means are respectively provided in the circulating means and the first to third exhausting means.

Abstract: Disclosed are, for example, a process for producing a tricarboxylic acid tris(alkyl-substituted cyclohexylamide), the process comprising subjecting a tricarboxylic acid and an alkyl-substituted cyclohexylamine to an amidation reaction, either (a) in the presence of a boric acid compound and a phenol compound or (b) in the presence of a boric acid ester obtained by the dehydration condensation of a boric acid compound and a phenol compound, and optionally purifying the resulting crude reaction product.

Abstract: The present invention relates to a peptide comprising an amino acid sequence identical to or substantially identical to an amino acid sequence represented by SEQ ID NO: 35 and having an ability of binding to a receptor protein comprising an amino acid sequence identical to or substantially identical to an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or a precursor thereof, its amide or ester, or a salt thereof. An inventive peptide-encoding DNA or equivalent can be employed in (1) a development of a receptor binding assay system using an expression system of a recombinant receptor protein and a screening for a pharmaceutical candidate compound, and (2) a development of a pharmaceutical having a reduced side effect such as a memory function improving agent, an appetite improving agent, an uterine, renal, prostatic, testicular or skeletal muscle function regulating agent.

Abstract: The present invention relates to a peptide comprising an amino acid sequence identical to or substantially identical to an amino acid sequence represented by SEQ ID NO: 35 and having an ability of binding to a receptor protein comprising an amino acid sequence identical to or substantially identical to an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or a precursor thereof, its amide or ester, or a salt thereof. An inventive peptide-encoding DNA or equivalent can be employed in (1) a development of a receptor binding assay system using an expression system of a recombinant receptor protein and a screening for a pharmaceutical candidate compound, and (2) a development of a pharmaceutical having a reduced side effect such as a memory function improving agent, an appetite improving agent, an uterine, renal, prostatic, testicular or skeletal muscle function regulating agent.

Abstract: The present invention relates to a peptide comprising an amino acid sequence identical to or substantially identical to an amino acid sequence represented by SEQ ID NO: 35 and having an ability of binding to a receptor protein comprising an amino acid sequence identical to or substantially identical to an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or a precursor thereof, its amide or ester, or a salt thereof. An inventive peptide-encoding DNA or equivalent can be employed in (1) a development of a receptor binding assay system using an expression system of a recombinant receptor protein and a screening for a pharmaceutical candidate compound, and (2) a development of a pharmaceutical having a reduced side effect such as a memory function improving agent, a appetite improving agent, an uterine, renal, prostatic, testicular or skeletal muscle function regulating agent.

Abstract: The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, and the like, and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, and the like, but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Wili syndrome and the like.

Abstract: This invention discloses a PACAP receptor protein or a salt thereof, a DNA comprising a DNA fragment coding for the protein, a method for preparing the protein, antibody against the protein and use of the protein, DNA and antibodies.

Abstract: This invention discloses a PACAP receptor protein or a salt thereof, a DNA comprising a DNA fragment coding for the protein, a method for preparing the protein, antibody against the protein, and use of the protein, DNA, and antibodies. A PACAP receptor protein was purified from the bovine cerebrum. DNAs coding for PACAP receptor proteins were isolated from bovine, rat and human cDNA libraries, and their nucleotide sequences were determined. Further, amino acid sequences deduced from the nucleotide sequences were determined.

Abstract: This invention discloses a PACAP receptor protein or a salt thereof, a DNA comprising a DNA fragment coding for the protein, a method for preparing the protein, antibody against the protein and use of the protein, DNA and antibodies.

Abstract: The present invention relates to a pituitary adenylate cyclase activating polypeptide (PACAP) receptor protein or a salt thereof which is capable of binding PACAP and a method for preparing said receptor protein or salt thereof.

Abstract: A ferroelectric memory device according to the present invention includes memory cells. Each memory cell is constructed such that a lower electrode is formed on a silicon substrate, a ferroelectric capacitor having a hysteresis characteristic with at least two non-linear characteristic portions is formed on the lower electrode, and an upper electrode is formed on the ferroelectric capacitor. The memory cells are arranged in a matrix and are provided with a column switching controller and a row switching controller. These controllers are connected via a switching circuit to a write circuit, a read circuit and a detector. When a voltage lower than a coercive voltage is applied to the memory cells, the data storage states of the memory cells are discriminated on the basis of the difference in differential dielectric constants between "1" and "0", thus reading out the data in a non-destructive manner.

Abstract: An acoustic device has an acoustic wave propagating medium exhibiting elastic abnormality in the vicinity of a Curie temperature. It is desirable that such an acoustic wave propagating medium be formed of a ferroelectric substance or a high-elastic substance and, in particular, have a Curie temperature at normal temperatures. For example, such ferroelectric substance is a solid solution expressed by Cs(Pb.sub.1-x Sr.sub.x)(Cl.sub.1-y Br.sub.y).sub.3 or (Bi.sub.1-x Dy.sub.x)VO.sub.4. By changing values of x and y appropriately, the Curie temperature of the solid solution can be varied, and an acoustic wave propagating medium meeting the purpose of use can be obtained. In such an acoustic wave propagating medium, an elastic coefficient C.sup.P at the time of constant polarization differs greatly from an elastic coefficient C.sup.E at the time of a constant electric field in the vicinity of the Curie temperature. Accordingly, the propagation velocity of acoustic waves is greatly different, too.